Systemic Immune-Inflammation Index and Platelet Parameters in Diabetic Kidney Disease | NCT07773467 | Trialant

Not yet recruitingObservationalUpdated Aug 19, 2026

Systemic Immune-Inflammation Index and Platelet Parameters in Diabetic Kidney Disease

Systemic Immune Inflammation Index With Related Blood Ratios and Platelet Parameters in Patients With Type 2 Diabetes Mellitus and Nephropathy

Overview

Key facts that identify this study and show where it stands today.

What the study is about and why it is being run, in the researchers' own words.

Official Title: Systemic Immune Inflammation Index With Related Blood Ratios and Platelet Parameters in Patients With Type 2 Diabetes Mellitus and Nephropathy
Brief Summary: Diabetic kidney disease (DKD) is a frequent microvascular complication in individuals with type 2 diabetes mellitus (T2DM) and a major cause of chronic kidney failure worldwide. Chronic low-grade inflammation and platelet activation contribute significantly to renal microvascular damage.

The purpose of this observational study is to evaluate whether routine blood test markers, specifically the Systemic Immune-Inflammation Index (SII), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and platelet indices (such as mean platelet volume [MPV] and platelet distribution width [PDW]), can serve as simple, accessible, and cost-effective biomarkers for identifying the presence and progression of diabetic kidney disease.

Participants will include adult patients with type 2 diabetes categorized according to their urinary albumin-to-creatinine ratio (normoalbuminuria, microalbuminuria, and macroalbuminuria) as well as healthy control subjects. Complete blood counts, derived inflammatory indices, and renal parameters will be measured to assess their diagnostic accuracy for DKD.

The medical conditions and diseases this study investigates.

The treatments and procedures being evaluated in this study.

No interventions

There are no interventions for this study.

Who can join this study and the criteria used to decide.

Ages Eligible for Study: Adult (18-64)Older Adult (65+)
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No data available
Eligibility Criteria: Inclusion Criteria:

Adults aged 18 to 80 years, both males and females.

Confirmed clinical diagnosis and history of Type 2 Diabetes Mellitus (T2DM).

Healthy control subjects matched for age and sex (for the control cohort).

Exclusion Criteria:

Type 1 diabetes mellitus.

Acute infections or clinical signs of active inflammation at the time of sampling.

Chronic inflammatory or autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus).

Known or recently diagnosed malignancies.

Chronic liver diseases, including cirrhosis or hepatitis.

Nephrotic syndrome or other known non-diabetic kidney diseases.

History of immunosuppressive therapy, systemic corticosteroids, or cytotoxic medications within the past 3 months prior to enrollment.

Pregnancy.

Significant cardiovascular complications.

How the study is designed and how its participant groups are organized.

The people to reach with questions about this study or how to join it.

No central contacts

There are no central contacts for this study.

Where the study is run and whether each site is currently recruiting.

No locations

There are no locations for this study.

The organizations and people involved in this study.

Other registered studies that closely resemble this one.